Skip to main content Accessibility help
×
Home

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

  • G. M. Mandolini (a1), M. Lazzaretti (a1), A. Pigoni (a1), L. Oldani (a1), G. Delvecchio (a2) and P. Brambilla (a2) (a3)...

Abstract

Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders. In conclusion, current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties. However, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
      Available formats
      ×

Copyright

Corresponding author

*Address for correspondence: Paolo Brambilla, Department of Neurosciences and Mental Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, via F. Sforza 35, 20122 Milan, Italy. (Email: paolo.brambilla1@unimi.it)

Footnotes

Hide All

This Section of Epidemiology and Psychiatric Sciences appears in each issue of the Journal to stress the relevance of epidemiology for behavioral neurosciences, reporting the results of studies that explore the use of an epidemiological approach to provide a better understanding of the neural basis of major psychiatric disorders and, in turn, the utilisation of the behavioural neurosciences for promoting innovative epidemiological research.

The ultimate aim is to help the translation of most relevant research findings into every-day clinical practice. These contributions are written in house by the journal's editorial team or commissioned by the Section Editor (no more than 1000 words, short unstructured abstract, 4 key-words, one Table or Figure and up to ten references).

Paolo Brambilla, Section Editor

Footnotes

References

Hide All
Bergamaschi, MM, Queiroz, RHC, Chagas, MHN, De Oliveira, DCG, De Martinis, BS, Kapczinski, F, Quevedo, J, Roesler, R, Schröder, N, Nardi, AE, Martín-Santos, R, Hallak, JEC, Zuardi, AW, Crippa, JAS (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-nave social phobia patients. Neuropsychopharmacology 36, 1219.
Boggs, DL, Surti, T, Gupta, A, Gupta, S, Niciu, M, Pittman, B (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Schizophrenia Bulletin 44, 4653.
Bonnet, U, Preuss, U (2017). The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation 8, 937.
Campos, AC, Moreira, FA, Gomes, FV, Del Bel, EA, Guimaraes, FS (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences 367, 33643378.
Crippa, JAS, Nogueira Derenusson, G, Borduqui Ferrari, T, Wichert-Ana, L, Duran, FLS, Martin-Santos, R, Vinícius Simões, M, Bhattacharyya, S, Fusar-Poli, P, Atakan, Z, Santos Filho, A, Freitas-Ferrari, MC, McGuire, PK, Zuardi, AW, Busatto, GF, Hallak, JEC (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology 25, 121130.
Crippa, JAS, Hallak, JEC, Machado-De-Sousa, JP, Queiroz, RHC, Bergamaschi, M, Chagas, MHN, Zuardi, AW (2013). Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. Journal of Clinical Pharmacy and Therapeutics 38, 162164.
de Mello Schier, AR, de Oliveira Ribeiro, NP, Coutinho, DS, Machado, S, Arias-Carrión, O, Crippa, JA, Zuardi, AW, Nardi, AE, Silva, AC (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets 13, 953960.
Di Marzo, V, Petrosino, S (2007). Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology 18, 129140.
Fasinu, PS, Phillips, S, ElSohly, MA, Walker, LA (2016). Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36, 781796.
Gururajan, A, Malone, DT (2016). Does cannabidiol have a role in the treatment of schizophrenia? Schizophrenia Research 176, 281290.
Hahn, B (2018). The potential of cannabidiol treatment for cannabis users with recent-onset psychosis. Schizophrenia Bulletin 44, 4653.
Hallak, JEC, Machado-de-Sousa, JP, Crippa, JAS, Sanches, RF, Trzesniak, C, Chaves, C, Bernardo, SA, Regalo, SC, Zuardi, AW (2010). Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Revista Brasileira de Psiquiatria 32, 5661.
Laprairie, RB, Bagher, AM, Kelly, MEM, Denovan-Wright, EM (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology 172, 47904805.
Lee, JLC, Bertoglio, LJ, Guimarães, FS, Stevenson, CW (2017). Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. British Journal of Pharmacology 174, 32423256.
Leweke, M (2013). The endocannabinoid system in schizophrenia-a mechanistically new approach to its pathophysiology and treatment. Schizophrenia Bulletin 39, S341.
Leweke, FM, Piomelli, D, Pahlisch, F, Muhl, D, Gerth, CW, Hoyer, C, Klosterkötter, J, Hellmich, M, Koethe, D (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2, e94.
Lötsch, J, Weyer-Menkhoff, I, Tegeder, I (2018). Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. European Journal of Pain (United Kingdom) 22, 471484.
McGuire, P, Robson, P, Cubala, WJ, Vasile, D, Morrison, PD, Barron, R, Taylor, A, Wright, S (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. The American Journal of Psychiatry 175, 225231.
Morgan, CJA, Das, RK, Joye, A, Curran, HV, Kamboj, SK (2013). Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive Behaviors 38, 24332436.
Osborne, AL, Solowij, N, Weston-Green, K (2017). A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neuroscience and Biobehavioral Reviews 72, 310324.
Parker, LA, Rock, EM, Limebeer, CL (2011). Correspondence regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology 163, 14111422.
Perucca, E (2017). Cannabinoids in the treatment of epilepsy: hard evidence at last? Journal of Epilepsy Research 7, 6176.
Pisanti, S, Malfitano, AM, Ciaglia, E, Lamberti, A, Ranieri, R, Cuomo, G, Abate, M, Faggiana, G, Proto, MC, Fiore, D, Laezza, C, Bifulco, M (2017). Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacology and Therapeutics 175, 133150.
Prud'Homme, M, Cata, R, Jutras-Aswad, D (2015). Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance Abuse: Research and Treatment 9, 3338.
Rodríguez-Muñoz, M, Sánchez-Blázquez, P, Merlos, M, Garzón-Niño, J (2016). Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction. Oncotarget 7, 5584055862.
Russo, EB, Burnett, A, Hall, B, Parker, KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research 30, 10371043.
Seeman, P (2016). Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry 6, e920.
Shannon, S, Opila-Lehman, J (2015). Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integrative Medicine (Encinitas) 14, 31.
Soares, VP, Campos, AC (2017). Evidences for the anti-panic actions of cannabidiol. Current Neuropharmacology 15, 291299.
Watt, G, Karl, T (2017). In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease. Frontiers in Pharmacology 8, 20.
Zuardi, AW, Morais, SL, Guimaraes, FS, Mechoulam, R (1995). Antipsychotic effect of cannabidiol [3]. Journal of Clinical Psychiatry 56, 485486.
Zuardi, AW, Hallak, JEC, Dursun, SM, Morais, SL, Sanches, RF, Musty, RE, Crippa, JAS (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology 20, 683686.
Zuardi, AW, Crippa, JAS, Hallak, JEC, Pinto, JP, Chagas, MHN, Rodrigues, GGR, Dursun, SM, Tumas, V (2009). Cannabidiol for the treatment of psychosis in Parkinsons disease. Journal of Psychopharmacology 23, 979983.
Zuardi, AW, Crippa, JAS, Dursun, SM, Morais, SL, Vilela, JAA, Sanches, RF, Hallak, JEC (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology 24, 135137.

Keywords

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

  • G. M. Mandolini (a1), M. Lazzaretti (a1), A. Pigoni (a1), L. Oldani (a1), G. Delvecchio (a2) and P. Brambilla (a2) (a3)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed